MCID: KRT006
MIFTS: 53

Keratoconjunctivitis

Categories: Eye diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Keratoconjunctivitis

MalaCards integrated aliases for Keratoconjunctivitis:

Name: Keratoconjunctivitis 12 54 44 15 70 32

Classifications:



External Ids:

Disease Ontology 12 DOID:9368
ICD9CM 34 370.40
MeSH 44 D007637
NCIt 50 C34744
SNOMED-CT 67 155154005
ICD10 32 B30.0 H16.2
UMLS 70 C0022573

Summaries for Keratoconjunctivitis

MalaCards based summary : Keratoconjunctivitis is related to vernal keratoconjunctivitis and keratoconjunctivitis sicca. An important gene associated with Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ganciclovir and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and salivary gland, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 73 Keratoconjunctivitis is inflammation ("-itis") of the cornea and... more...

Related Diseases for Keratoconjunctivitis

Diseases related to Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 844)
# Related Disease Score Top Affiliating Genes
1 vernal keratoconjunctivitis 32.6 RNASE3 IL5 IL4 IL13 CCL24 CCL11
2 keratoconjunctivitis sicca 32.6 TNF NGF MUC5AC IL4
3 neurotrophic keratoconjunctivitis 32.2 NGF MUC5AC
4 punctate epithelial keratoconjunctivitis 31.8 NGF MUC5AC MUC16
5 tropical spastic paraparesis 31.7 MMP9 IL6 IL2 IFNG
6 dry eye syndrome 31.6 TNF NGF MUC5AC IL6
7 atopic keratoconjunctivitis 31.5 RNASE3 MUC5AC MUC16 IL5 IL4 IL3
8 keratopathy 30.8 TNF IL4 ICAM1 CXCL8
9 ige responsiveness, atopic 30.8 RNASE3 IL5 IL4 IL13 IFNG
10 cytokine deficiency 30.8 IL5 IL13
11 corneal ulcer 30.7 NGF MUC5AC MMP9 CCL11
12 dacryoadenitis 30.6 IL4 IL17A IL13
13 dysentery 30.6 TNF IL6 CXCL8
14 vernal conjunctivitis 30.6 RNASE3 MUC5AC IL4 IFNG
15 graft-versus-host disease 30.5 TNF IL6 IL2 IFNG
16 keratitis, hereditary 30.5 TNF NGF MMP9 IL6 IL17A CXCL8
17 cellulitis 30.4 TNF RNASE3 IL6 IL5
18 papillary conjunctivitis 30.4 IL6 IL4 CXCL8 CCL24 CCL11
19 hypopyon 30.3 TNF IL6 IL17A
20 acquired immunodeficiency syndrome 30.3 TNF IL6 IL2 IFNG ICAM1
21 chlamydia pneumonia 30.2 TNF IL6 IL4 CXCL8
22 trachoma 30.2 TNF IL6 IL4 IL17A
23 chlamydia 30.2 TNF IL6 IL5 IL4 IL17A IFNG
24 iridocyclitis 30.2 TNF IL6 IL17A
25 alopecia 30.2 TNF IL4 IL2 IFNG
26 endophthalmitis 30.2 TNF IL6 ICAM1 CXCL8
27 giant papillary conjunctivitis 30.2 RNASE3 IL6 IL4 CXCL8 CCL24 CCL11
28 pharyngitis 30.1 TNF IL6 CXCL8
29 chickenpox 30.1 TNF IL6 IL4 IL2 IFNG
30 conjunctivochalasis 30.1 MMP9 IL6 CXCL8
31 blepharitis 30.1 TNF MUC5AC MUC16 MMP9 IL4 CXCL8
32 scleritis 30.1 TNF MMP9 IL5 IL4 IFNG
33 optic neuritis 30.0 TNF IL6 CXCL8
34 allergic conjunctivitis 30.0 TNF RNASE3 IL5 IL4 IL2 IL13
35 vaccinia 30.0 TNF IL6 IL2 ICAM1
36 toxoplasmosis 30.0 TNF IL6 IL5 IL4 IFNG
37 neurodermatitis 30.0 TSLP IL4 IL13
38 disease by infectious agent 30.0 TNF IL6 IL4 IL2 IL17A IFNG
39 plague 29.9 TNF IL6 IL2
40 iritis 29.9 TNF IL6 IL17A
41 pollen allergy 29.9 RNASE3 IL5 IL3 IL13 ICAM1
42 measles 29.9 TNF IL6 IL2 IFNG CD46
43 ocular cicatricial pemphigoid 29.9 RNASE3 NGF IL4
44 hidradenitis 29.9 TNF IL17A IFNG
45 hidradenitis suppurativa 29.9 TNF IL17A IFNG
46 rosacea 29.9 TNF MMP9 IL6 IL17A CXCL8
47 bacterial conjunctivitis 29.9 TNF MUC16 IL6 CXCL8
48 exanthem 29.9 TNF IL6 IL2 IFNG CXCL8
49 purpura 29.9 TNF IL6 IL4 IFNG
50 thyroiditis 29.9 TNF IL6 IL4 IL2 IL17A IFNG

Comorbidity relations with Keratoconjunctivitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Keratoconjunctivitis:



Diseases related to Keratoconjunctivitis

Symptoms & Phenotypes for Keratoconjunctivitis

MGI Mouse Phenotypes related to Keratoconjunctivitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 CCL11 CCL24 ICAM1 IFNG IL13 IL17A
2 digestive/alimentary MP:0005381 10.21 ICAM1 IFNG IL13 IL17A IL2 IL4
3 immune system MP:0005387 10.21 CCL11 CCL24 ICAM1 IFNG IL13 IL17A
4 integument MP:0010771 10.02 ICAM1 IFNG IL13 IL17A IL4 IL6
5 neoplasm MP:0002006 9.8 ICAM1 IFNG IL2 IL5 IL6 MMP9
6 respiratory system MP:0005388 9.73 CCL11 CCL24 IFNG IL13 IL17A IL2
7 no phenotypic analysis MP:0003012 9.7 IFNG IL13 IL17A IL2 IL4 NGF
8 vision/eye MP:0005391 9.32 CD46 ICAM1 IFNG IL2 IL4 IL6

Drugs & Therapeutics for Keratoconjunctivitis

Drugs for Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Povidone Approved Phase 4 9003-39-8 131751496
4
Povidone-iodine Approved Phase 4 25655-41-8
5
Iodine Approved, Investigational Phase 4 7553-56-2 807
6
Glycerol Approved, Investigational Phase 4 56-81-5 753
7
Rebamipide Approved, Investigational Phase 4 90098-04-7
8
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
9
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
10
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
11
Iron Approved Phase 4 7439-89-6 23925 29936
12
Travoprost Approved Phase 4 157283-68-6 5282226
13
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
14
Zinc Approved, Investigational Phase 4 7440-66-6 32051
15
Azithromycin Approved Phase 4 83905-01-5 55185 447043
16
Ethanol Approved Phase 4 64-17-5 702
17
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
18
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
19
Menthol Approved Phase 4 2216-51-5 16666
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
22
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
23
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
26
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
27
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
28
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
29
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
30
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
31
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
32
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
33
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
34
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
35
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
36
Cadexomer iodine Experimental Phase 4 94820-09-4
37
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
38 Ganciclovir triphosphate Phase 4
39 Anti-Infective Agents, Local Phase 4
40 Plasma Substitutes Phase 4
41 Blood Substitutes Phase 4
42 Olive Phase 4
43 Guar Phase 4
44 Antacids Phase 4
45 Anti-Ulcer Agents Phase 4
46 Cathartics Phase 4
47 Laxatives Phase 4
48 Analgesics, Non-Narcotic Phase 4
49 Analgesics Phase 4
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4

Interventional clinical trials:

(show top 50) (show all 692)
# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
3 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
4 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
5 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
6 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
7 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
8 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
9 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
10 A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis Unknown status NCT03237936 Phase 4 1mg/mL ciclosporin
11 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
12 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
13 Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca. Completed NCT01797822 Phase 4 Dexamethasone;Artificial tear
14 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
15 A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye Completed NCT02139033 Phase 4 Retaine™
16 A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine Completed NCT00407043 Phase 4 Lotemax;Restasis
17 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
18 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
19 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
20 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
21 Treatment of Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: Corticosteroids Versus Cyclosporine Eyedrops: A Randomized Double-blind Study Completed NCT04376970 Phase 4 FLUCON®;Cyclosporine A eye drops 0.5%
22 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
23 Efficacy, Tolerability and Comfort of 0.3% Hypromellose Eyedrops in the Pre- and Post-Operative Treatment of Patients Undergoing LASIK Surgery Completed NCT00909324 Phase 4 Pre-LASIK 0.3% hypromellose;Post-LASIK 0.3% hypromellose
24 The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study Completed NCT00809198 Phase 4
25 An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z® Completed NCT00799682 Phase 4 Xalatan;Travatan Z
26 Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
27 Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort Completed NCT03682809 Phase 4 Systane Complete
28 Randomized Assessor Masked Trial Comparing Manuka Honey Eye Drops to Conventional Treatment of Meibomian Gland Dysfunction Related Dry Eye Disease. Completed NCT04457648 Phase 4
29 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
30 Evaluation of Intraoperative Use of Dexycu on the Signs and Symptoms of Dry Eye Completed NCT04184999 Phase 4 dexamethasone intraocular suspension, 9%;Prednisolone Acetate 1% Oph Susp
31 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
32 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
33 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
34 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
35 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
36 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
37 A Randomized Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
38 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
39 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
40 Comparison of Autologous Serum Versus Preservative Free Artificial Tear in Patients With Dry Eye Due to Systemic Isotretinoin Therapy Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
41 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
42 The Comparison of 50 % Concentration Autologous Serum Eye Drops Versus Preservative Free Artificial Eye Drop Plus 0.05 % Cyclosporin Ophthalmic Emulsion in the Treatment of Severe Dry Eye Syndrome: A Randomized Comparative Study Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
43 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
44 Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients Completed NCT01311609 Phase 4
45 Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
46 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
47 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
48 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
49 Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients Completed NCT00520260 Phase 4 bromfenac;ketorolac
50 Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears Completed NCT01614847 Phase 4 Artificial tears

Search NIH Clinical Center for Keratoconjunctivitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Lodoxamide
lodoxamide tromethamine

Cochrane evidence based reviews: keratoconjunctivitis

Genetic Tests for Keratoconjunctivitis

Anatomical Context for Keratoconjunctivitis

MalaCards organs/tissues related to Keratoconjunctivitis:

40
Eye, Skin, Salivary Gland, Bone Marrow, Lung, Heart, Tongue

Publications for Keratoconjunctivitis

Articles related to Keratoconjunctivitis:

(show top 50) (show all 4609)
# Title Authors PMID Year
1
Ocular complications of autoimmune polyendocrinopathy syndrome type 1. 61 54
17189144 2006
2
Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. 54 61
10682966 2000
3
Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. 54 61
10606937 2000
4
Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. 61 54
10469030 1999
5
Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. 61 54
10359913 1999
6
Nocardia keratitis mimicking superior limbic keratoconjunctivitis and herpes simplex virus. 61
33665477 2021
7
Conjunctival Inclusion Cysts in Chronic Vernal Keratoconjunctivitis: String of Pearls. 61
33745524 2021
8
Pulsed oral corticosteroids for the treatment of vernal and atopic keratoconjunctivitis: a management plan. 61
32612172 2021
9
Ocular Anterior Segment Pathology in the Emergency Department: A 5-Year Study. 61
32568931 2021
10
Adding evidence to the role of NEUROG1 in congenital cranial dysinnervation disorders. 61
33439489 2021
11
Cost Savings From a Policy to Diagnose and Prevent Transmission of Adenoviral Conjunctivitis in Employees of a Large Academic Medical Center. 61
33792644 2021
12
Pachydermoperiostosis Presenting With Vision Loss Secondary to Severe Phlyctenular Keratoconjunctivitis. 61
33758137 2021
13
Efficacy of 2% Rebamipide Suspension for Vernal Keratoconjunctivitis: A Clinical Comparison with Topical Immune Modulators Cyclosporine and Tacrolimus. 61
33764241 2021
14
Comparative profile of ocular surface microbiome in vernal keratoconjunctivitis patients and healthy subjects. 61
33651203 2021
15
Corneal and lens densitometry with Pentacam HR in children with vernal keratoconjunctivitis. 61
32945010 2021
16
Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: a Prospective Randomized Controlled Study. 61
33654316 2021
17
Clinical efficacy and safety of omalizumab in conventional treatment-resistant vernal keratoconjunctivitis: Our experience and literature review. 61
33434384 2021
18
Chemical disinfectants in ophthalmic practice. 61
33595464 2021
19
Tear film break-up patterns in thyroid eye disease. 61
33674648 2021
20
Intense Pulsed Light Treatment for Itch Associated with Allergic Keratoconjunctivitis: A Retrospective Study of 35 Cases. 61
33625273 2021
21
Corneal and lens densitometry in patients with vernal keratoconjunctivitis. 61
33754236 2021
22
Role of combined immunomodulator therapy in severe steroid intolerant vernal keratoconjunctivitis. 61
32518397 2021
23
Visual rehabilitation by using corneal wavefront-guided transepithelial photorefractive keratectomy for corneal opacities after epidemic keratoconjunctivitis. 61
33730316 2021
24
Systemic diseases and the cornea. 61
33485845 2021
25
IgA immunoglobulin isotype of rheumatoid factor in primary Sjögren's syndrome. 61
33496802 2021
26
Ophthalmologic Manifestations of Primary Sjögren's Syndrome. 61
33806489 2021
27
Comparative efficacy of medical treatments for vernal keratoconjunctivitis in children and young adults: a systematic review with network meta-analyses. 61
33779061 2021
28
Recurrent keratoconjunctivitis as the sole manifestation of COVID-19 infection: A case report. 61
33781126 2021
29
Glomerulonephritis with severe nephrotic syndrome induced by immune complexes composed of galactose-deficient IgA1 in primary Sjögren's syndrome: a case report. 61
33765955 2021
30
Molecular Detection and Identification of Chlamydiaceae in the Eyes of Wild and Domestic Ruminant Hosts from Northern Spain. 61
33806840 2021
31
Systematic evaluation of laryngeal impairment in Sjögren's syndrome. 61
33765165 2021
32
BLK and BANK1 variants and interactions are associated with susceptibility for primary Sjögren's syndrome and with some clinical features. 61
33756160 2021
33
Cataract Surgery Destabilises Temporary the Tear Film of the Ocular Surface. 61
32659842 2021
34
[Simple limbal epithelial transplantation (SLET) : A simple technique for the treatment of unilateral complete limbal stem cell deficiency. Video article]. 61
33683425 2021
35
Efficacy of compartmentalization in controlling an adenovirus type 54 keratoconjunctivitis outbreak on Oki Island, Japan. 61
33634367 2021
36
Tear N-glycomics in vernal and atopic keratoconjunctivitis. 61
33583051 2021
37
Dual Molecular Diagnosis of Microsporidia (Encephalitozoon hellem) Keratoconjunctivitis in an Immunocompetent Adult. 61
32826651 2021
38
Relatedness of type IV pilin PilA amongst geographically diverse Moraxella bovoculi isolated from cattle with infectious bovine keratoconjunctivitis. 61
33404383 2021
39
Cellular miR-101-1 Reduces Efficiently the Replication of HSV-1 in HeLa Cells. 61
33626544 2021
40
A polymeric aqueous tacrolimus formulation for topical ocular delivery. 61
33571621 2021
41
Whole-genome analysis to describe a human adenovirus D8 conjunctivitis outbreak in a tertiary hospital. 61
33543795 2021
42
Immunobiology of T Cells in Sjögren's Syndrome. 61
32390096 2021
43
Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases. 61
33522964 2021
44
A rare case of primary sinonasal tuberculosis presented with phlyctenular keratoconjunctivitis in a pediatric patient: A case report and literature review. 61
33607832 2021
45
Long-term Outcomes of Punctal Cauterization in the Management of Ocular Surface Diseases. 61
32467449 2021
46
The Impact of Surgical Excision of the Orbital Lacrimal Gland on the Aqueous Tear Production and Ocular Surface Health in Donkeys (Equus asinus). 61
33478769 2021
47
Clinical features and outcomes from the Singapore Sjögren's syndrome study. 61
33259751 2021
48
Association between atopic keratoconjunctivitis and the risk of keratoconus. 61
32567209 2021
49
Adenovirus diseases: a systematic review and meta-analysis of 228 case reports. 61
32720128 2021
50
Current Knowledge in Allergic Conjunctivitis. 61
33631915 2021

Variations for Keratoconjunctivitis

Expression for Keratoconjunctivitis

Search GEO for disease gene expression data for Keratoconjunctivitis.

Pathways for Keratoconjunctivitis

Pathways related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF RNASE3 MUC5AC MUC16 MMP9 IL6
2
Show member pathways
13.93 TNF NGF IL6 IL5 IL4 IL3
3
Show member pathways
13.8 TSLP TNF NGF IL6 IL5 IL4
4
Show member pathways
13.64 TNF NGF IL6 IL5 IL4 IL3
5
Show member pathways
13.54 TNF NGF IL6 IL5 IL4 IL3
6
Show member pathways
13.46 TNF MMP9 IL6 IL5 IL4 IL3
7
Show member pathways
13.43 TNF NGF IL6 IL5 IL4 IL3
8
Show member pathways
13.27 TNF MMP9 IL6 IL2 IFNG ICAM1
9
Show member pathways
13.05 TNF NGF IL6 IL4 IL3 IL2
10 13.01 MMP9 IL6 IL5 IL4 IL3 IL2
11
Show member pathways
12.94 TNF IL6 IL2 IFNG ICAM1 CXCL8
12
Show member pathways
12.77 TNF NGF IL6 IL3 IL2
13
Show member pathways
12.77 TNF IL6 IL5 IL4 IL2 IL17A
14
Show member pathways
12.75 TNF IL6 IL5 IL4 IL2 IL17A
15 12.72 TNF IL4 IL3 IL2 IL17A IFNG
16
Show member pathways
12.66 TNF IL6 IL2 IL17A IFNG
17
Show member pathways
12.66 TNF IL5 IL4 IL3 IL13
18
Show member pathways
12.65 TNF IL4 IL3 IL2 IFNG ICAM1
19
Show member pathways
12.6 TSLP IL6 IL5 IL4 IL3 IL2
20
Show member pathways
12.48 TNF IL6 IL4 IL2 IFNG ICAM1
21
Show member pathways
12.48 TNF IL6 IL2 CXCL8 CCL24 CCL11
22
Show member pathways
12.4 ICAM1 CXCL8 CCL24 CCL11
23 12.4 TNF IL6 IL2 ICAM1
24
Show member pathways
12.35 TNF IL6 IL4 IFNG CXCL8 CCL11
25
Show member pathways
12.35 TNF NGF IL6 IL5 IL4 IL3
26 12.33 MMP9 IL6 IL3 CXCL8
27 12.31 TNF NGF IL6 IL13 CXCL8
28
Show member pathways
12.29 TNF MUC5AC IL6 CXCL8
29 12.26 TNF MMP9 IL6 IFNG
30 12.18 TNF IL6 IL5 IL4 IL3 IL2
31 12.18 TNF MMP9 IL6 IL4 IL2 IFNG
32
Show member pathways
12.18 TNF RNASE3 IL6 IL5 IL4 IL3
33 12.17 TNF MMP9 IFNG ICAM1
34 12.16 TNF IL6 IL2 CXCL8
35 12.07 TNF MMP9 IL6 ICAM1
36 12.07 TNF IL6 IL5 IL4 IL3
37 12.07 TNF IL6 IL17A IFNG ICAM1 CXCL8
38 12.04 IL6 IL3 IFNG CXCL8
39 12.03 TNF MMP9 IL6 IL4 IL17A IL13
40
Show member pathways
12.03 TNF MUC5AC MMP9 IL6 IL5 IL4
41 12.02 TNF IL6 IFNG CXCL8
42 12.01 TNF IL6 ICAM1 CXCL8
43 11.99 IL6 IL5 IL4 IL2 IL13 IFNG
44
Show member pathways
11.98 IL6 IL17A ICAM1 CXCL8
45
Show member pathways
11.97 IL6 IL4 IL17A IFNG
46 11.96 TSLP TNF IL5 IL4 IL2 IL17A
47
Show member pathways
11.95 TNF IL5 IL4 IL3 IL2 IFNG
48
Show member pathways
11.93 TNF IL6 IL2 IL17A IFNG
49 11.87 TNF IL6 IL2 IFNG
50 11.86 TNF IL6 IL5 IL4 ICAM1

GO Terms for Keratoconjunctivitis

Cellular components related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 TSLP TNF RNASE3 NGF MUC5AC MUC16
2 extracellular space GO:0005615 9.6 TSLP TNF RNASE3 NGF MUC5AC MUC16

Biological processes related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.11 TSLP NGF MMP9 IL6 IL4 IL2
2 positive regulation of cell proliferation GO:0008284 10.09 TSLP IL6 IL5 IL4 IL3 IL2
3 cell-cell signaling GO:0007267 10.02 IL3 IL2 IL17A CCL24
4 positive regulation of gene expression GO:0010628 10.01 TNF NGF IL6 IL4 IL13 IFNG
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 TNF ICAM1 CCL24 CCL11
6 positive regulation of protein phosphorylation GO:0001934 10 TNF MMP9 IL2 IFNG
7 cellular response to lipopolysaccharide GO:0071222 9.98 TNF IL6 ICAM1 CXCL8
8 chemotaxis GO:0006935 9.96 RNASE3 CXCL8 CCL24 CCL11
9 cellular response to tumor necrosis factor GO:0071356 9.95 ICAM1 CXCL8 CCL24 CCL11
10 defense response to Gram-positive bacterium GO:0050830 9.92 TNF RNASE3 IL6 IL17A
11 inflammatory response GO:0006954 9.92 TNF IL6 IL5 IL17A IL13 CXCL8
12 neutrophil chemotaxis GO:0030593 9.89 CXCL8 CCL24 CCL11
13 regulation of insulin secretion GO:0050796 9.89 TNF IL6 IFNG
14 chemokine-mediated signaling pathway GO:0070098 9.89 CXCL8 CCL24 CCL11
15 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.89 TSLP RNASE3 CXCL8
16 positive regulation of inflammatory response GO:0050729 9.89 TSLP TNF IL2 IFNG CCL24
17 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 IL6 IL5 IL3 ICAM1
18 defense response to Gram-negative bacterium GO:0050829 9.88 TSLP RNASE3 IL6 IL17A
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 TNF IL6 IL13
20 humoral immune response GO:0006959 9.86 TNF IL6 IFNG
21 positive regulation of actin filament polymerization GO:0030838 9.86 ICAM1 CCL24 CCL11
22 positive regulation of T cell proliferation GO:0042102 9.86 IL6 IL4 IL2 CD46
23 positive regulation of interleukin-6 production GO:0032755 9.85 TSLP TNF IL6 IL17A IFNG
24 positive regulation of interleukin-1 beta production GO:0032731 9.84 TNF IL6 IL17A IFNG
25 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 TNF IFNG ICAM1
26 monocyte chemotaxis GO:0002548 9.83 IL6 CCL24 CCL11
27 positive regulation of B cell proliferation GO:0030890 9.83 IL5 IL4 IL2 IL13
28 cellular response to interleukin-1 GO:0071347 9.83 IL17A ICAM1 CXCL8 CCL24 CCL11
29 negative regulation of endothelial cell apoptotic process GO:2000352 9.82 IL4 IL13 ICAM1
30 positive regulation of chemokine production GO:0032722 9.81 TSLP TNF IL6 IFNG
31 positive regulation of JAK-STAT cascade GO:0046427 9.8 TNF IL6 IL5
32 negative regulation of neurogenesis GO:0050768 9.78 TNF IL6 CCL11
33 microglial cell activation GO:0001774 9.78 TNF IL4 IL13 IFNG
34 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.77 TNF IL6 IL17A
35 positive regulation of osteoclast differentiation GO:0045672 9.77 TNF IL17A IFNG
36 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 TSLP TNF IL6 IL4 IL3 IL2
37 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.74 TNF IL6 ICAM1
38 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
39 regulation of neuroinflammatory response GO:0150077 9.73 MMP9 IL6
40 immune response GO:0006955 9.73 TNF IL6 IL5 IL4 IL3 IL2
41 positive regulation of podosome assembly GO:0071803 9.72 TNF IL5
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 IL4 IFNG
43 positive regulation of interleukin-13 production GO:0032736 9.72 TSLP IL4
44 negative regulation of T-helper 17 cell differentiation GO:2000320 9.71 IL4 IL2
45 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 IL4 IL2
46 positive regulation of mast cell degranulation GO:0043306 9.7 IL4 IL13
47 negative regulation of lipid storage GO:0010888 9.7 TNF IL6
48 vascular endothelial growth factor production GO:0010573 9.69 TNF IL6
49 positive regulation of mononuclear cell migration GO:0071677 9.68 TNF IL4
50 positive regulation of STAT cascade GO:1904894 9.68 TSLP IL6

Molecular functions related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.44 TSLP TNF IL6 IL5 IL4 IL3
2 chemokine activity GO:0008009 9.43 CXCL8 CCL24 CCL11
3 growth factor activity GO:0008083 9.43 NGF IL6 IL5 IL4 IL3 IL2
4 CCR3 chemokine receptor binding GO:0031728 9.16 CCL24 CCL11

Sources for Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....